Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner after heart procedure: hope for artery health, but trial stopped short

NCT ID NCT03630055

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking the blood thinner rivaroxaban for 7 days after heart catheterization via the wrist could prevent the wrist artery from becoming blocked. About 930 adults were planned, but the trial was stopped early. The main goal was to see if the artery stayed open at 30 days, while also checking for major bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rivaroxaban (Xarelto), a blood thinner
What this could lead to
If it worked, a short course of rivaroxaban could reduce the risk of radial artery blockage after heart catheterization, preserving the artery for future use.
What could go wrong
The trial was terminated early, so we don't have enough data to know if it works or is safe. Blood thinners like rivaroxaban also raise the risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

930 people

The number who actually took part.

Started

Oct 2018

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to provide written informed consent 2. Age ≥ 18 years 3. Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach Exclusion Criteria: 1. Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site 2. Access or attempted access at a second site - including contralateral radial artery, brachial, or femoral artery or vein 3. Planned staged procedure, CABG or noncardiac surgery within 30 days 4. Contraindication or high risk of bleeding with anticoagulation 1. bleeding requiring medical attention in the previous 6 months 2. thrombocytopenia (platelets\<50 x 109/L) 3. prior intracranial hemorrhage 4. use of IIb/IIIa during percutaneous coronary intervention 5. administration of thrombolytic therapy in the preceding 24 hours 6. use of non-steroidal anti-inflammatory medications 7. ischemic stroke or transient ischemic attack diagnosed in the last 3 months 5. Cardiogenic shock 6. Ventricular arrhythmias refractory to treatment 7. Liver dysfunction (Child-Pugh class B or C) 8. Unexplained anemia with a Hgb below 100 g/L 9. History of medication noncompliance or risk factor for noncompliance 10. Active malignancy 11. Allergy to rivaroxaban 12. Another indication for anticoagulation 13. CYP3A4 and P-glycoprotein inhibitor use 14. Life expectancy \<30 days 15. Women capable of pregnancy not on birth control 16. Chronic kidney disease with creatinine clearance of less than 30mL/min 17. History of antiphosphopholipid antibody syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Radial artery occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arterial occlusion Arterial Occlusive Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radial artery occlusion

Contacts and locations

Locations

  • Kingston Health Sciences Center

    Kingston, Ontario, K7L 2V7, Canada

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.